^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CEBPA mutation

i
Other names: CEBPA, CCAAT Enhancer Binding Protein Alpha, CCAAT/Enhancer Binding Protein (C/EBP), Alpha, CCAAT/Enhancer-Binding Protein Alpha, CEBP, CCAAT/Enhancer Binding Protein Alpha, C/EBP-Alpha, C/EBP Alpha
Entrez ID:
Phase 2
Masonic Cancer Center, University of Minnesota
Recruiting
Last update posted :
05/07/2024
Initiation :
05/01/2023
Primary completion :
10/22/2027
Completion :
10/22/2028
NPM1 • KMT2A • IKZF1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C
|
NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation
|
cyclophosphamide • sirolimus • fludarabine IV
Phase 2
Masonic Cancer Center, University of Minnesota
Recruiting
Last update posted :
04/16/2024
Initiation :
03/30/2018
Primary completion :
01/10/2025
Completion :
11/10/2025
NPM1 • KMT2A • IKZF1 • CEBPA
|
NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation
|
cyclophosphamide
Phase 2
Masonic Cancer Center, University of Minnesota
Active, not recruiting
Last update posted :
04/10/2024
Initiation :
01/02/2019
Primary completion :
06/23/2020
Completion :
06/28/2024
FLT3 • NPM1 • KMT2A • HLA-DRB1 • CEBPA
|
FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type
|
cyclophosphamide • melphalan • fludarabine IV • busulfan • cyclophosphamide intravenous • spanlecortemlocel (MGTA-456)
Phase 2
Washington University School of Medicine
Active, not recruiting
Last update posted :
04/02/2024
Initiation :
07/06/2016
Primary completion :
07/31/2033
Completion :
07/31/2033
FLT3 • NPM1 • CEBPA
|
FLT3-ITD mutation • NPM1 mutation • CEBPA mutation
|
cytarabine • Rydapt (midostaurin)
Phase 2
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
03/01/2024
Initiation :
05/30/2024
Primary completion :
12/31/2025
Completion :
12/31/2025
TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA
|
TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation • CEBPA mutation
|
Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • Starasid (cytarabine ocfosfate)
Phase 1/2
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
01/10/2024
Initiation :
02/27/2019
Primary completion :
01/31/2025
Completion :
01/31/2025
ABL1 • BCR • NPM1 • PDGFRA • PDGFRB • CEBPA
|
NPM1 mutation • CEBPA mutation • PDGFRA rearrangement
|
Venclexta (venetoclax) • azacitidine • pevonedistat (MLN4924)
Phase 2
wang, jianxiang
Recruiting
Last update posted :
10/05/2023
Initiation :
06/01/2020
Primary completion :
06/01/2024
Completion :
06/01/2025
CEBPA
|
CEBPA mutation
|
cytarabine
Phase 2
University Hospital Heidelberg
Completed
Last update posted :
03/27/2023
Initiation :
10/22/2019
Primary completion :
02/28/2023
Completion :
03/24/2023
FLT3 • CEBPA
|
CEBPA mutation
|
cytarabine • bortezomib • Mylotarg (gemtuzumab ozogamicin)
Phase 2
Masonic Cancer Center, University of Minnesota
Active, not recruiting
Last update posted :
02/24/2023
Initiation :
05/15/2017
Primary completion :
02/22/2023
Completion :
12/01/2029
NPM1 • KMT2A • IKZF1 • CEBPA
|
NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation
|
cyclophosphamide • sirolimus • fludarabine IV • cyclophosphamide intravenous
Phase 3
Medical College of Wisconsin
Completed
Last update posted :
12/01/2021
Initiation :
06/01/2012
Primary completion :
09/11/2020
Completion :
09/11/2020
NPM1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C
|
NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation
|
cyclophosphamide • fludarabine IV
Phase N/A
PETHEMA Foundation
Recruiting
Last update posted :
09/06/2021
Initiation :
10/01/2019
Primary completion :
10/01/2022
Completion :
10/01/2022
TP53 • FLT3 • IDH2 • NPM1 • RUNX1 • WT1 • CEBPA • PHF6 • RAD21 • BRINP3 • SMC1A
|
NPM1 mutation • U2AF1 mutation • CEBPA mutation
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
08/22/2019
Initiation :
01/29/2011
Primary completion :
06/28/2018
Completion :
06/28/2018
FLT3 • NPM1 • CEBPA • CD4 • IL15 • IL7 • KIR2DS2
|
FLT3-ITD mutation • NPM1 mutation • CEBPA mutation • Chr del(5q)
Phase 2
Masonic Cancer Center, University of Minnesota
Withdrawn
Last update posted :
12/02/2017
Initiation :
06/01/2016
Primary completion :
09/01/2018
Completion :
09/01/2018
NPM1 • KMT2A • HLA-DRB1 • CEBPA • HLA-B
|
NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation
|
cyclophosphamide • fludarabine IV • cyclophosphamide intravenous
Phase N/A
Children's Oncology Group
Completed
Last update posted :
05/07/2015
Initiation :
01/01/2010
Primary completion :
06/01/2010
Completion :
06/01/2010
CEBPA • MIR34A • E2F3 • MIR194
|
CEBPA mutation • miR-34a overexpression • miR-34a underexpression